Sanofi extended the deal again last year to cover another STAT6 degrader, and, two months ago, the French pharma paid out $15 million for the rights to a once-undruggable transcription factor.

The cover art for 1Type's first single. (Sanofi) The song also features a spoken word interlude by Duke Al Durham, a U.K.-based poet and hip-hop artist who also has Type 1 diabetes.

Sanofi’s shares fell following mixed results of its experimental drug for a deadly lung condition. Itepekimab, a medicine that is being jointly developed by Sanofi and Regeneron, is being tested ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial. A second test of the drug, itepekimab, was successful.

Sanofi has been active in the M&A market this year, picking up Dren Bio’s clinical-stage bispecific antibody, DR-0201, for $600 million upfront and another $1.3 billion in milestones. Last month ...

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

Sanofi SAN-0.18 % decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.16 % increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest ...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and ...

Sanofi’s R&D site in Vitry-Sur-Seine, near Paris. Sanofi and Regeneron said that drug candidate Itepekimab didn’t hit the main objective of a second trial.

Karnataka's Health and Family Welfare Department has said in an official statement that the number of active Covid-19 cases crossed the 300-mark in the state.

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Read more about why SNY is still a Buy.